The pathway for biosimilar approval in the US has been set. But are US patients too far behind Europe?
Philip Ridley-Smith
Advertisement
Philip Ridley-Smith is the business development and marketing manager at RecipharmCobra Biologics
Articles by Philip Ridley-Smith
Advertisement
Latest Updated Articles
Biosimilars Regulation in the US: The ChallengesPublished: November 1st 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5
